Seborrheic Dermatitis Clinical Trial
Official title:
Petrolatum's Effect on Initial Symptoms of Nonscalp Seborrheic Dermatitis and Preventing Exacerbation
NCT number | NCT01315951 |
Other study ID # | ME 10 0054 |
Secondary ID | |
Status | Terminated |
Phase | N/A |
First received | |
Last updated | |
Start date | March 2011 |
Est. completion date | March 2012 |
Verified date | May 2024 |
Source | Ascension Health |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this research is to demonstrate the use of petroleum jelly in prevention of nonscalp seborrheic dermatitis exacerbations at the first signs of a flare. In doing so, it will decrease the chronic use of topical steroids. The use of petrolatum should have favorable outcomes for patients, without the side-effects.
Status | Terminated |
Enrollment | 3 |
Est. completion date | March 2012 |
Est. primary completion date | February 2012 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Age 18-75 years old who are patients of the Genesys East Flint Clinic and have been diagnosed with recurrent NSSD - Patients are to use the petrolatum treatment strictly for the initial symptoms of NSSD: Excessive flaking, and erythematous macules or papules - Patients who are able to attend the follow-up appointments for assessment - Patients are to have the doctor's confidence that that patient will correctly implement the treatment plan Exclusion Criteria: - Patients not in the 18-75 years of age range. - Patients who are receiving treatment for their seborrheic dermatitis (Scalp or nonscalp) elsewhere. - Patients who have not demonstrated recurrent NSSD. - Patients who are unable to commit to a follow-up appointments for assessment. - Patients who do not have the physician's confidence in implementing the studies treatment plan effectively. - Patient's who are unable/unwilling to have petrolatum on affected area for at least a 6 hour length of time. |
Country | Name | City | State |
---|---|---|---|
United States | Genesys East Flint Campus | Burton | Michigan |
Lead Sponsor | Collaborator |
---|---|
Ascension Health |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Measuring the Effectiveness of Petroleum Jelly in Treating Nonscalp Seborrheic Dermatitis | Petroleum jelly will be applied to the areas of the face affected by Nonscalp Seborrheic Dermatitis every other night for four weeks. Patients will be seen in the office at one week, two weeks, and one month during the course of the treatment. Pictures will be taken at each visit to determine the progress of the treatment. | 4 weeks | |
Secondary | Patient Satisfaction ofTreatment | Patients will be surveyed initially when they are consented asking about their personal history of nonscalp seborrheic dermatitis including triggers and previous and current treatment measures. | 4 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01703793 -
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
|
Phase 2 | |
Completed |
NCT01203189 -
Seborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo
|
N/A | |
Completed |
NCT00991198 -
The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage
|
Phase 2 | |
Completed |
NCT03567980 -
A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis
|
Phase 4 | |
Recruiting |
NCT03688971 -
Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis
|
Phase 2 | |
Recruiting |
NCT01139749 -
Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea
|
Phase 4 | |
Completed |
NCT05105139 -
Study to Evaluate the Safety of Sebryl® and Sebryl Plus® in Seborrheic Dermatitis and Psoriasis of Scalp
|
||
Completed |
NCT01591070 -
Proactive Treatment of Tacrolimus Ointment for Adult Facial Seborrheic Dermatitis
|
Phase 4 | |
Completed |
NCT05787860 -
Ruxolitinib in Seborrheic Dermatitis
|
Phase 2 | |
Completed |
NCT00403559 -
A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis
|
Phase 2 | |
Not yet recruiting |
NCT00767546 -
Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients
|
Phase 1 | |
Recruiting |
NCT05942248 -
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
|
N/A | |
Recruiting |
NCT06013371 -
PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea
|
Phase 2 | |
Recruiting |
NCT05319444 -
Cleansing Device for the Treatment of Scalp and Hair Conditions
|
N/A | |
Completed |
NCT04445987 -
Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
|
Phase 2 | |
Completed |
NCT04973228 -
Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)
|
Phase 3 | |
Completed |
NCT03114111 -
Pilot Study for the Use of Photodynamic Therapy in the Treatment of Seborrheic Dermatitis
|
Early Phase 1 | |
Completed |
NCT02656368 -
Safety and Efficacy of SEBORRHEAMEDIS Face Cream in Patients With Seborrheic Dermatitis
|
N/A | |
Completed |
NCT00830908 -
HairMax LaserComb Open Label Study to Treat Seborrheic Dermatitis
|
N/A | |
Completed |
NCT02349854 -
Neurobiology of the Scalp in Seborrheic Dermatitis
|
N/A |